Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Cited by (1,000)

Items 201–300 of 1,000

1. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
   Sirle Saul, Shirit Einav · 2020 · ACS Infectious Diseases
2. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019
   Stephan D. Fihn, Eli N. Perencevich, Steven M. Bradley · 2020 · JAMA Network Open
3. COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks
   Markus F. Blaess, Lars Kaiser, Martin Sauer, René Csük, Hans‐Peter Deigner · 2020 · International Journal of Molecular Sciences
4. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19
   Sarah M Lofgren, Melanie R. Nicol, Ananta Shrikant Bangdiwala, Katelyn A Pastick, Elizabeth C Okafor, Caleb P Skipper, Matthew F Pullen, Nicole Wyman Engen, Mahsa Abassi, Darlisha A Williams et al. · 2020 · Open Forum Infectious Diseases
5. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
   Ennio Giulio Favalli, Serena Bugatti, Catherine Klersy, Martina Biggioggero, Silvia Rossi, Orazio De Lucia, Francesca Bobbio‐Pallavicini, Antonella Murgo, Silvia Balduzzi, Roberto Felice Caporali et al. · 2020 · Arthritis Research & Therapy
6. COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations
   Bin Zhou, Shinsuke Kojima, Atsuhiko Kawamoto, Masanori Fukushima · 2020 · Journal of Medical Virology
7. Precision therapeutic targets for COVID-19
   Zachary A. Krumm, Grace M. Lloyd, Connor P. Francis, Lith H. Nasif, Duane A. Mitchell, Todd Eliot Golde, Benoit I. Giasson, Yuxing Xia · 2021 · Virology Journal
8. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation
   Bero, Lisa, Lawrence, Rosa, Leslie, Louis, Chiu, Kellia, McDonald, Sally, Page, Matthew J, Grundy, Quinn, Parker, Lisa, Boughton, Stephanie, Kirkham, Jamie J et al. · 2021 · BMJ Open
9. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline
   Serena Bugatti, Ludovico De Stefano, Francesca Bobbio‐Pallavicini, Carlomaurizio Montecucco · 2020 · RMD Open
10. Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
    Bianza Moïse Bakadia, Feng He, Tiatou Souho, Lallepak Lamboni, Muhammad Wajid Ullah, Biaou Oscar Ode Boni, Abeer Ahmed Qaed Ahmed, Biampata Mutu Mukole, Guang Yang · 2020 · Biomedicine & Pharmacotherapy
11. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
    Álvaro Réa-Neto, Rafaella Stradiotto Bernardelli, Bruna Martins Dzivielevski Câmara, Fernanda Baeumle Reese, Marcos Vinícius Oliveira Queiroga, Mirella Cristine de Oliveira · 2021 · Scientific Reports
12. Treatment of SARS-CoV-2: How far have we reached?
    Waquar Ahsan, Shamama Javed, Mohammed Al Bratty, Hassan A. Alhazmi, Asim Najmi · 2020 · Drug Discoveries & Therapeutics
13. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review
    Chaturaka Rodrigo, Sumadhya Deepika Fernando, Senaka Rajapakse · 2020 · Clinical Microbiology and Infection
14. COVID ‐19 and the heart: An update for clinicians
    Ahmed M. Goha, Kenechukwu N. Mezue, Paul A. Edwards, Felix Nunura, Dainia S. Baugh, Ernest C. Madu · 2020 · Clinical Cardiology
15. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
    Eli Mansour, André C. Palma, Raisa Gusso Ulaf, Luciana C. Ribeiro, Ana Flávia Bernardes, Thyago A. Nunes, Marcus Vinicius Rodrigues de Agrela, Bruna Bombassaro, Milena Monfort‐Pires, Rafael Ludemann Camargo et al. · 2021 · Viruses
16. SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities
    Marcin Filip Osuchowski, Federico Mario Aletti, Jean‐Marc Cavaillon, Stefanie B. Flohé, Evangelos J. Giamarellos‐Bourboulis, Markus Stefan Huber-Lang, Borna Relja, Tomasz Skirecki, Andrea Szabó, Marc Maegele · 2020 · Shock
17. Novel therapeutic approaches for treatment of COVID-19
    Nikoo Hossein‐Khannazer, Bahare Shokoohian, Anastasia I. Shpichka, Hamid Asadzadeh Aghdaei, Peter S. Timashev, Massoud Vosough · 2020 · Journal of Molecular Medicine
18. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    Teodoro J. Oscanoa, Román Romero‐Ortuño, Alfonso Carvajal, Andrea Savarino · 2020 · International Journal of Antimicrobial Agents
19. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis
    Rashmi Ranjan Das, Nishant Jaiswal, Nishanth Dev, Nikita Jaiswal, Sushree Samiksha Naik, Jhuma Sankar · 2020 · Frontiers in Medicine
20. Severity of COVID‐19 in pregnancy: A review of current evidence
    Lauren M. Kucirka, Alexandra Norton, Jeanne S. Sheffield · 2020 · American Journal of Reproductive Immunology
21. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
    The Task Force for the management of COVID-19 of the European Society of Cardiology, Colin Baigent, Stephan Windecker, Daniele Andreini, Elena Arbelo, Emanuele Barbato, Antonio Luca Bartorelli, Andreas Baumbach, Elijah Raphael Behr, Sérgio Luis Berti et al. · 2021 · Cardiovascular Research
22. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19
    Madalina Elena Carter-Timofte, Sofie E. Jørgensen, Mette Ratzer Freytag, Michelle M. Thomsen, Nanna-Sophie Brinck Andersen, Ali Al-Mousawi, Alon Schneider Hait, Trine Hyrup Mogensen · 2020 · Frontiers in Immunology
23. Pharmacological treatments of COVID-19
    Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, Asal Tanzifi, Fatemeh Faramarzi, Reza Negarandeh, Mohammadreza Safdari et al. · 2020 · Pharmacological Reports
24. Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications
    Mainul Haque, Santosh Kumar, Jaykaran Charan, Rohan Bhatt, Salequl Islam, Siddhartha Dutta, Jha Pallavi Abhayanand, Yesh Sharma, Israel Abebrese Sefah, Amanj Baker Kurdi et al. · 2021 · Frontiers in Pharmacology
25. Novel coronavirus disease (COVID-19) pandemic: A recent mini review
    Muhammad Fayyaz ur Rehman, Chaudhary Fariha, Aqsa Anwar, Naveed Shahzad, Munir Ahmad, Salma Mukhtar, Muhammad Farhan Ul Haque · 2020 · Computational and Structural Biotechnology Journal
26. Identification of Drug Interaction Adverse Events in Patients With COVID-19
    Valeria Conti, Carmine Sellitto, Martina Torsiello, Valentina Manzo, Emanuela De Bellis, Berenice Stefanelli, Nicola Bertini, Maria Costantino, Chiara Maci, Emanuel Raschi et al. · 2022 · JAMA Network Open
27. Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic
    Gianluca Costamagna, Elena Abati, Nereo Bresolin, Giacomo P. Comi, Stefania Paola Corti · 2020 · Journal of Neurology
28. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy
    Chandler, Laurel, Yusuf, Imran, McClements, Michelle, Barnard, Alun, MacLaren, Robert, Xue, Kanmin · 2020 · International Journal of Molecular Sciences
29. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics
    Ramesh J. L. Kandimalla, Albin A John, Chandrika Abburi, Jayalakshmi Vallamkondu, P. Hemachandra Reddy · 2020 · Molecular Neurobiology
30. Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand
    Wannarat Amornnimit Pongpirul, Surasak Wiboonchutikul, Lantharita Charoenpong, Nayot Panitantum, Apichart Vachiraphan, Sumonmal Uttayamakul, Krit Pongpirul, Weerawat Manosuthi, Wisit Prasithsirikul · 2020 · PLoS neglected tropical diseases
31. Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture
    Zixuan Yuan, Mahmud Arif Pavel, Hao Wang, Jerome C. Kwachukwu, Sonia Mediouni, Joseph Anthony Jablonski, K.W. Nettles, Chakravarthy B. Reddy, Susana T. Valente, Scott B. Hansen · 2022 · Communications Biology
32. Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression
    Runzhen Zhao, Zhenlei Su, Andrey A. Komissarov, Shan‐Lu Liu, Guohua Yi, Steven Idell, Michael A. Matthay, Hong‐Long Ji · 2021 · Frontiers in Immunology
33. No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”
    Subodh Kumar Pathak, Abhijeet Ashok Salunke, Praveen S Thivari, Apurva Kumari Pandey, Kunal NANDY, Harish V K Ratna, Dr Sanjay Pandey, Jasneet Singh Chawla, Jalil Mujawar, Anant Dhanwate et al. · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
34. Current evidence for COVID-19 therapies: a systematic literature review
    Tobias Welte, Lucy Ambrose, Gillian C. Sibbring, Shehla Sheikh, Hana Müllerová, Ian N. Sabir · 2021 · European Respiratory Review
35. RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
    Hany Mansour Dabbous, Manal Hamdy El-Sayed, Gihan El Assal, Hesham A. Elghazaly, Fatma Soliman Elsayed Ebeid, Ahmed Fouad Sherief, Maha Elgaafary, Ehab Fawzy, Sahar Mohamed Hassany, Ahmed Radwan Riad et al. · 2021 · Scientific Reports · Retracted
36. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
    Hamid Motamedi, Marzie Mahdizade Ari, Shirin Dashtbin, Matin Fathollahi, Hadi Hossainpour, Amirhooshang Alvandi, Jale Moradi, Ramin Abiri · 2021 · International Immunopharmacology
37. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
    Zeynab Mohamadi Yarijani, Houshang Najafi · 2021 · Biomedicine & Pharmacotherapy
38. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines
    Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang · 2021 · Biomedicine & Pharmacotherapy
39. Misinformation on social networks during the novel coronavirus pandemic: a quali-quantitative case study of Brazil
    Priscila Biancovilli, Lilla Makszin, Cláudia Jurberg · 2021 · BMC Public Health
40. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019
    Yishay Szekely, Yael Lichter, Bander Abu Shrkihe, Hila Bruck, Howard S. Oster, Sami Viskin · 2020 · Heart Rhythm
41. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system
    Cian P. McCarthy, Sean Murphy, Maeve Jones‐O’Connor, David S. Olshan, Jay Khambhati, Saad C. Rehman, John B. Cadigan, Jinghan Cui, Eric Allan Meyerowitz, George J. Philippides et al. · 2020 · EClinicalMedicine
42. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
    Mário Roberto Senger, Tereza Cristina Santos Evangelista, Rafael Ferreira Dantas, Marcos V. Santana, Luiz Carlos Saramago Gonçalves, Lauro Ribeiro de Souza Neto, Sabrina Baptista Ferreira, Floriano Paes Silva · 2020 · Memórias do Instituto Oswaldo Cruz
43. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
    Jung‐Hyun Won, Howard Lee · 2020 · International Journal of Molecular Sciences
44. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021
    Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin‐Rong Zhou, S. M. Abdur Rahman, Isa Naina Mohamed · 2021 · Frontiers in Pharmacology
45. Clinical and cardiac characteristics of COVID‐19 mortalities in a diverse New York City Cohort
    Mark P. Abrams, Elaine Y. Wan, Marc Waase, John Morrow, Jose M. Dizon, Hirad Yarmohammadi, Jeremy P. Berman, Geoffrey Allan Rubin, Alexander Kushnir, Timothy Joseph Poterucha et al. · 2020 · Journal of Cardiovascular Electrophysiology
46. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
    Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Viktoria Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper Tidemandsen et al. · 2021 · European Respiratory Journal
47. Is rapid scientific publication also high quality? Bibliometric analysis of highly disseminated COVID ‐19 research papers
    Amandeep Khatter, Michael Naughton, Hajira Dambha‐Miller, Patrick Redmond · 2021 · Learned Publishing
48. Arrhythmias and electrocardiographic findings in Coronavirus disease 2019: A systematic review and meta‐analysis
    Sebastián García-Zamora, Sharen Lee, Sohaib Haseeb, George Bazoukis, Gary Tse, Jesus Alvarez Garcia, Enes Elvin Gül, Göksel Çinier, Bryce Alexander, Marcelo Martins Pinto Filho et al. · 2021 · Pacing and Clinical Electrophysiology
49. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity
    Julianna Desmarais, James Todd Rosenbaum, Karen H. Costenbader, Ellen M. Ginzler, Nicole M. Fett, Susan M. Goodman, James R. O’Dell, Christian A. Pineau, Gabriela Schmajuk, Victoria P. Werth et al. · 2021 · Arthritis & Rheumatology
50. Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery
    Michael F. Cuccarese, Berton A. Earnshaw, Katie Heiser, Ben Fogelson, Chadwick T. Davis, Peter McLean, Hannah B. Gordon, Kathleen-Rose Skelly, Fiona L. Weathersby, Vlad Rodic et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
51. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
    Shaozhe Cai, Wei Sun, Ming Li, Lingli Dong · 2020 · Clinical Rheumatology
52. Beyond the Surface: Endocytosis of Mosquito-Borne Flaviviruses
    Stephen D. Carro, Sara R. Cherry · 2020 · Viruses
53. Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock
    Shmeylan A. Al Harbi, Hasan M. Al‐Dorzi, Albatool Al Meshari, Hani Tamim, Sheryl Ann Abdukahil, Musharaf Sadat, Yaseen M. Arabi · 2021 · BMC Pharmacology and Toxicology
54. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review
    Jahangir Emrani, Maryam Ahmed, Liesl K. Jeffers-Francis, John C. Teleha, Chishimba Nathan Mowa, Robert Howard Newman, Misty D. Thomas · 2021 · International Journal of Biological Macromolecules
55. COVID-19 Drug Development
    Seungtaek Kim · 2021 · Journal of Microbiology and Biotechnology
56. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
    Adrián Vladimir Hernández, Yuani M. Roman, Vinay Pasupuleti, Joshuan J. Barboza, Charles Michael White · 2020 · Annals of Internal Medicine
57. Trajectory of the COVID-19 pandemic: chasing a moving target
    Kamal Kant Sahu, Ajay Kumar Mishra, Amos Lal · 2020 · Annals of Translational Medicine
58. COVID-19 : physiopathologie d’une maladie à plusieurs visages
    Vincent Bonny, Alexis Maillard, Cyril Mousseaux, Léo Plaçais, Quentin Richier · 2020 · La Revue de Médecine Interne
59. Targeting protein-protein interaction interfaces in COVID-19 drug discovery
    Chung‐ke Chang, Shanmeng Lin, Roshan Satange, Shih‐Chao Lin, Sin-Cih Sun, Hung‐Yi Wu, Kylene Kehn‐Hall, Ming‐Hon Hou · 2021 · Computational and Structural Biotechnology Journal
60. COVID-19 and acute kidney injury
    Lale A. Ertuğlu, Asiye Kanbay, Barış Afşar, Rengin Elsürer Afşar, Mehmet Kanbay · 2020 · Tuberkuloz ve Toraks
61. Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019
    Zhiyao Wei, Yong‐Jian Geng, Ji Huang, Hai‐Yan Qian · 2020 · European Journal of Heart Failure
62. Evaluation of the Sexual Functioning of Individuals Living in Turkey During the COVID-19 Pandemic: An Internet-Based Nationwide Survey Study
    Nejdet Karşıyakalı, Yusuf Şahin, Hüseyin Aytaç Ateş, Emrah Okucu, Emre Karabay · 2020 · Sexual Medicine
63. Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations
    Edward J. Calabrese, Walter J. Kozumbo, Rachna Kapoor, Gaurav Dhawan, Pedro C. Lara, James Giordano · 2021 · Radiotherapy and Oncology
64. A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
    Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, Senthilkumar Natesan, Dewi Megawati, Karam Pal Singh, Izabela Michalak, Kuldeep Dhama · 2022 · Narra J
65. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19
    Jonathan Dale Casey, Nicholas James Johnson, Matthew W. Semler, Sean P. Collins, Neil R. Aggarwal, Roy G. Brower, Steven Y. Chang, John C. Eppensteiner, Michael R. Filbin, Kevin W. Gibbs et al. · 2020 · Annals of the American Thoracic Society
66. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval
    Sharmeen Samuel, Richard A. Friedman, Chetan Sharma, Madhusudan Ganigara, Elizabeth Mitchell, Charles L. Schleien, Andrew D. Blaufox · 2020 · Heart Rhythm
67. Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses
    J. R. Li, Ester Boix · 2021 · Virulence
68. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic
    Scott Martin Vouri, Thuy Nhu Thai, Almut Gertrud Winterstein · 2020 · Research in Social and Administrative Pharmacy
69. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
    Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, Grazia Graziani · 2020 · Biochemical Pharmacology
70. Emerging technologies for diagnostics and drug delivery in the fight against COVID-19 and other pandemics
    Dimitrios A. Lamprou · 2020 · Expert Review of Medical Devices
71. Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe
    Sunny Goel, Tarun Jain, Amit Hooda, Rohit Malhotra, Gurpreet Johal, Reza Masoomi, Haroon Kamran, Parasuram Melarcode Krishnamoorthy, Nagendra Boopathy Senguttuvan, Abhishek Sharma et al. · 2020 · Cardiology and Therapy
72. Emergency Nursing Care of Patients With Novel Coronavirus Disease 2019
    Katie Deitrick, Jourdan Adams, Joshua J. Davis · 2020 · Journal of Emergency Nursing
73. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2
    Arif Jamal Siddiqui, Sadaf Jahan, Syed Amir Ashraf, Mousa M. Alreshidi, Mohammad Saquib Ashraf, Mitesh B. Patel, Mejdi Snoussi, Ritu Singh, Mohd Adnan · 2020 · Journal of Biomolecular Structure and Dynamics
74. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis
    Donovan Anthony McGrowder, Fabian G. Miller, Melisa Anderson Cross, Lennox Anderson-Jackson, Sophia Bryan, Lowell Dilworth · 2021 · Diseases
75. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
    Matthieu Roustit, Romain Guilhaumou, Mathiéu Molimard, Milou‐Daniel Drici, Silvy Laporte, Jean‐Louis Montastruc · 2020 · Therapies
76. SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus
    Simona Alexandra Iacob, Diana Gabriela Iacob · 2020 · Frontiers in Pharmacology
77. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats
    Carlos Chaccour, Gloria Abizanda, Ángel Irigoyen Barrio, Aina Casellas, Azucena Aldaz, Fernando Martinez, Felix Hammann, Ana Gloria Gil · 2020 · Scientific Reports
78. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
    Leticia Rosario Cruz, Idania Baladrón, Aliusha Rittoles Navarro, Pablo A. Díaz, Carmen Valenzuela, Raúl Santana, María Margarita López Vázquez, Ariadna García, Deyli Chacón Montano, Delvin Thompson et al. · 2020 · ACS Pharmacology & Translational Science
79. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
    Hernando Gaitán‐Duarte, Carlos Álvarez, Carlos Rincón, Nancy Yomayusa González, Jorge Alberto Cortés, Juan Carlos Villar, Juan Sebastián Bravo-Ojeda, Ángel Alberto García-Peña, Wilson Adarme Jaimes, Viviana Rodríguez et al. · 2021 · EClinicalMedicine
80. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae
    Brandon Hamm, Lisa J. Rosenthal · 2020 · Psychosomatics
81. Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infoveillance Study
    Rafael A. Badell‐Grau, Jordan P. Cuff, Brendan P Kelly, Helen Waller‐Evans, Emyr Lloyd‐Evans · 2020 · Journal of Medical Internet Research
82. Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model
    Jianling Yang, Meng Wu, Xu Liu, Qi Liu, Zhengyang Guo, Xueting Yao, Yang Liu, Cheng Cui, Haiyan Li, Chunli Song et al. · 2020 · Frontiers in Pharmacology
83. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial
    Ilan Steven Schwartz, Mari E. Boesen, Graziela Cerchiaro, Craig Doram, Brett D. Edwards, Aravind Ganesh, Jamie Greenfield, Scott Jamieson, Vikram Karnik, Carol C Kenney et al. · 2021 · CMAJ Open
84. Combating COVID-19: Lessons learnt particularly among developing countries and the implications
    Brian Godman · 2020 · Bangladesh Journal of Medical Science
85. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients
    Adriana J. J. Lammers, Richard M. Brohet, R.E.P. Theunissen, Corinna Köster, R. Rood, Dominique W. M. Verhagen, Kees Brinkman, R.J. Hassing, A. Dofferhoff, Rachida el Moussaoui et al. · 2020 · International Journal of Infectious Diseases
86. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19
    JingKang Sun, YuTing Chen, Xiude Fan, Xiaoyun Wang, Qunying Han, Zhengwen Liu · 2020 · Postgraduate Medicine
87. Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis
    Núria Farré, Diana Mojón, Marc Llagostera, Laia Carla Belarte Tornero, Alicia Calvo-Fernández, Ermengol Vallès, Alejandro Negrete, Marcos García-Guimarães, Yolanda Bartolomé, Camino Fernández et al. · 2020 · Journal of Clinical Medicine
88. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery
    Yao Chen, Meixiu Li, Guo‐Dong Lu, Han‐Ming Shen, Jing Zhou · 2021 · International Journal of Biological Sciences
89. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial
    Samuel Morris Brown, Ithan D. Peltan, Naresh P. Kumar, Lindsay M. Leither, Brandon J. Webb, Nathan J. Starr, Colin K. Grissom, Whitney R. Buckel, Rajendu Srivastava, Allison M. Butler et al. · 2020 · Annals of the American Thoracic Society
90. Current COVID-19 treatments: Rapid review of the literature
    Yijia Dong, Azwa Shamsuddin, Harry J. Campbell, Evropi Τheodoratou · 2021 · Journal of Global Health
91. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Ilad Alavi Darazam, Shervin Shokouhi, Masoud Mardani, Mohamad Amin Pourhoseingholi, Mohammad Mahdi Rabiei, Firouze Hatami, Minoosh Shabani, Omid Moradi, Farid Javandoust Gharehbagh, Seyed Sina Naghibi Irvani et al. · 2021 · International Immunopharmacology
92. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
    Xinlei Li, Tao Peng · 2021 · Frontiers in Pharmacology
93. Risk of using hydroxychloroquine as a treatment of COVID-19
    Lo’ai Alanagreh, Foad Alzoughool, Manar Fayiz Mousa Atoum · 2020 · International Journal of Risk & Safety in Medicine
94. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis
    Christopher W. Jones, Ashley L. Woodford, Timothy F. Platts‐Mills · 2020 · BMJ Open
95. QTc prolongation in COVID ‐19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta‐analysis
    Carlos Diaz‐Arocutipa, Ana Brañez‐Condorena, Adrián Vladimir Hernández · 2021 · Pharmacoepidemiology and Drug Safety
96. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation
    Robert O. Bonow, Adrian F. Hernandez, Mintu P. Turakhia · 2020 · JAMA Cardiology
97. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
    Julian D. Machiels, Chantal P. Bleeker‐Rovers, Rob ter Heine, Janette C. Rahamat-Langendoen, Quirijn de Mast, Jaap ten Oever, Teun Bousema, Reinout van Crevel, Heiman F. L. Wertheim · 2020 · International Journal of Antimicrobial Agents
98. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID‐19 Infection
    Melanie R. Nicol, Abhay Joshi, Matthew L. Rizk, Philip E. Sabato, Radojka M. Savić, DAVID L. WESCHE, Jenny Zheng, Jack Cook · 2020 · Clinical Pharmacology & Therapeutics
99. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
    Filippo Albani, Federica Fusina, Alessia Giovannini, Pierluigi Ferretti, Anna Granato, Chiara Prezioso, Danilo Divizia, Alessandra Sabaini, Marco Marri, Elena Malpetti et al. · 2020 · Journal of Clinical Medicine
100. Câncer e Doenças Cardiovasculares na Pandemia de COVID-19
     Lucas Tokio Kawahara, Isabela Bispo Santos da Silva Costa, Cecília Chie Sakaguchi Barros, Gabriel Coelho de Almeida, Cristina Salvadori Bittar, Stéphanie Itala Rizk, Laura Testa, Camila Motta Venchiarutti Moniz, Juliana C. Pereira, Gláucia Maria Moraes de Oliveira et al. · 2020 · Arquivos Brasileiros de Cardiologia